Sionna Therapeutics, Inc. SION 深 滬
等待開盤 08-13 09:30:00 美东时间
20.99
+0.960
+4.79%
華盛通- 最 高21.7016
- 今 開19.89
- 成交量 42.10万股
- 最 低 19.89
- 昨 收 20.03
- 總市值 9.26亿
- 52周最高 25.19
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 7.255
- 委 比 -53.49%
- 總股本 4412.44万
- 歷史最高 25.19
- 量 比 2.95
- 振 幅 9.04%
- 歷史最低 7.255
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sionna Therapeutics Non-GAAP EPS of -$0.41
Sionna Therapeutics press release (NASDAQ:SION): Q2 Non-GAAP EPS of -$0.41. Cash, cash equivalents, and marketable securities of $337.27M More on Sionna Therapeutics Historical earnings data for Sionn...
08-12 02:49
Sionna Therapeutics Q2 EPS $(0.41) Beats $(0.59) Estimate
Sionna Therapeutics (NASDAQ:SION) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.59) by 30.15 percent. This is a 84.87 percent increase over losses of $(2.71) per share
08-11 19:11
Sionna Therapeutics Reports Second Quarter 2025 Financial Results
Sionna Therapeutics announced positive phase 1 data for its NBD1 stabilizers, SION-719 and SION-451, showing good tolerability and meeting pharmacokinetic targets. The company plans to initiate a phase 2a trial for SION-719 in cystic fibrosis patients in late 2025 and a phase 1 trial for SION-451 in healthy volunteers in dual combinations also in late 2025. Sionna maintains a strong cash position of approximately $337.3 million, expected to fund ...
08-11 11:00
WESTERN MIDSTREAM ANNOUNCES SECOND-QUARTER 2025 RESULTS
EXECUTING ON CORE GROWTH STRATEGY AND REAFFIRMING 2025 FINANCIAL GUIDANCE RANGES Reported second-quarter 2025 Net income attributable to limited partners of $333.8 million, generating record...
08-07 04:07
WESTERN MIDSTREAM TO ACQUIRE ARIS WATER SOLUTIONS
Creates a differentiated Delaware Basin produced-water system, enhancing WES's ability to compete for new business development opportunities. The combined infrastructure creates a fully inte...
08-07 04:05
UroGen Pharma Announces 24-Month DOR Of 72.2% By Kaplan-Meier Estimate In Patients Who Achieved CR At Three Months From Phase 3 ENVISION Trial Of ZUSDURI For Intravesical Solution
24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%)PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma
08-05 20:07
WESTERN COPPER AND GOLD PROVIDES UPDATE ON ESE SUBMISSION
VANCOUVER, BC, July 15, 2025 /PRNewswire/ - Western Copper and Gold Corporation ("Western" or the "Company") (TSX: WRN) (NYSE American: WRN) is pleased to provide an update on its Environmen...
07-15 19:30
ZHAOJIN MINING(01818.HK):HAIYU GOLD MINE TO START OPERATING;GLOBAL EXPANSION UNDERWAY
Investment positives We resume coverage on Zhaojin Mining with an OUTPERFORM ra...
07-14 20:42
Pfizer’s ATGAM Study: Aiming for Safer Aplastic Anemia Treatment
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer...
07-12 00:21
程向东教授专访｜卡度尼利单抗胃癌适应症获批，推动中国胃癌免疫治疗再上新台阶
基于COMPASSION-15研究，2024年9月30日，国家药品监督管理局（NMPA）批准了康方生物独立自主研发的PD-1/CTLA-4双特异性抗体卡度尼利单...
07-08 08:35
